AbbVie Inc. Capital expenditures

Capital expenditures of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.


Highlights and Quick Summary

  • Capital expenditures for the quarter ending March 30, 2020 was $-125 Million (a -23.31% decrease compared to previous quarter)
  • Year-over-year quarterly Capital expenditures decreased by -2.34%
  • Annual Capital expenditures for 2019 was $-552 Million (a -13.48% decrease from previous year)
  • Annual Capital expenditures for 2018 was $-638 Million (a 20.6% increase from previous year)
  • Annual Capital expenditures for 2017 was $-529 Million (a 10.44% increase from previous year)
  • Twelve month Capital expenditures ending March 30, 2020 was $-570 Million (a 3.26% increase compared to previous quarter)
  • Twelve month trailing Capital expenditures decreased by -10.94% year-over-year
Trailing Capital expenditures for the last four month:
30 Mar '20 30 Dec '19 29 Sep '19 29 Jun '19
$-570 Million $-552 Million $-512 Million $-640 Million
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital expenditures of AbbVie Inc.

Most recent Capital expendituresof ABBV including historical data for past 10 years.

Interactive Chart of Capital expenditures of AbbVie Inc.

AbbVie Inc. Capital expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-125.0
2019 $-163.0 $-154.0 $-128.0 $-107.0 $-552.0
2018 $-123.0 $-282.0 $-114.0 $-119.0 $-638.0
2017 $-182.0 $-126.0 $-126.0 $-95.0 $-529.0
2016 $-114.0 $-113.0 $-131.0 $-121.0 $-479.0
2015 $-145.0 $-127.0 $-115.0 $-145.0 $-532.0
2014 $-153.0 $-180.0 $-142.0 $-137.0 $-612.0
2013 $-151.0 $-133.0 $-119.0 $-88.0 $-491.0
2012 $-95.0 $18.0 $-94.0 $-162.0 $-333.0
2011 $-104.41 $-63.17 $-91.09 $-96.85 $-356.0
2010 $-448.14 $-448.0
2009 $-312.56 $-312.57

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc., a research-based biopharmaceutical company, develops and markets pharmaceutical products in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a biologic therapy administered as an injection for autoimmune and intestinal diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the treatment of patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; and Janssen Biotech, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.